Experience with etanercept in an academic medical center: are infection rates increased?

Arthritis and Rheumatism
Kristine PhillipsJonathan S Coblyn

Abstract

There is little established information regarding the safety of antitumor necrosis factor therapies used outside the setting of clinical trials. This study evaluated the long-term safety and tolerability of open-label use of etanercept when used to treat patients with a variety of systemic rheumatic diseases. Reduction of concomitant corticosteroid and disease-modifying antirheumatic drug was also assessed. Retrospective medical record review of 180 patients who were started on etanercept between December 1998 and April 2000 at an academic medical center. Most patients (81%) remained on therapy for longer than 6 months, and a significant number (43%) of patients for longer than 12 months. Etanercept was prescribed for rheumatoid arthritis (RA) in 144 patients and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyositis, in 36 patients. Fifty-six percent of patients taking corticosteroids were able to reduce their dose and 51% of patients were able to taper their methotrexate dosages. Forty-three patients (26%) discontinued etanercept. Reasons for discontinuing therapy included serious adverse events (2.9%), of which infection was most common. These included a psoas abscess secondary to...Continue Reading

References

Apr 1, 1994·Arthritis and Rheumatism·F WolfeM A Cathey
Dec 1, 1995·Seminars in Arthritis and Rheumatism·R A Myllykangas-LuosujärviH A Isomäki
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·M W MarinoL J Old
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt

❮ Previous
Next ❯

Citations

Oct 2, 2002·Arthritis and Rheumatism·Michele F DoranSherine E Gabriel
Sep 1, 2005·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·G Wozel
Jan 15, 2008·Rheumatology International·A Holl-WiedenH J Girschick
Jan 20, 2006·Zeitschrift für Rheumatologie·A GaemperliR Speck
Aug 2, 2003·Journal of the American Academy of Dermatology·Mark Lebwohl
Jun 6, 2003·Best Practice & Research. Clinical Rheumatology·Gaye CunnaneBarry Bresnihan
Jun 30, 2007·Nature Clinical Practice. Rheumatology·Jakko van IngenDick van Soolingen
Feb 3, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Neil FosterPaul A Barrow
Dec 15, 2010·Rheumatology·Merete Lund Hetland
Apr 23, 2003·Current Opinion in Rheumatology·Aparna K MohanM Miles Braun
Jun 18, 2004·Current Opinion in Rheumatology·Carol Dukes Hamilton
Sep 9, 2005·Medicine·Nancy F CrumMark R Wallace
Jul 10, 2004·Annals of the Rheumatic Diseases·K L HyrichD P M Symmons
Oct 9, 2003·Annals of the Rheumatic Diseases·M FlendrieP L C M van Riel
Mar 25, 2008·Therapeutics and Clinical Risk Management·Boulos Haraoui, Vivian Bykerk
Feb 5, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Anne-Marie Tobin, Brian Kirby
Nov 28, 2007·American Journal of Clinical Dermatology·Efstathios RallisAndreas Katsambas
Oct 22, 2008·Journal of Neurosurgery. Spine·Adam P SmithJohn E O'Toole
Oct 21, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Georg HaerterMichael Schmitt
Apr 6, 2004·Scandinavian Journal of Infectious Diseases·Kyongwook YimMichael H Cynamon
Jun 2, 2009·Rheumatic Diseases Clinics of North America·Eduardo Acevedo-VásquezRocío Gamboa-Cárdenas
Nov 1, 2006·Reumatología clinica·Francisco Medina Rodríguez
Oct 9, 2007·The Journal of Infection·Edsel Maurice T SalvanaRobert A Salata
Nov 23, 2006·Infectious Disease Clinics of North America·Lesley Ann Saketkoo, Luis R Espinoza
Jun 9, 2005·International Journal of Dermatology·Mohanad BaklehElie F Berbari
Sep 17, 2005·Pharmacotherapy·David J Rychly, Joseph T DiPiro
Aug 27, 2005·The British Journal of Dermatology·C H SmithUNKNOWN British Association of Dermatologists
Apr 17, 2008·International Journal of Dermatology·Elizabeth C A SmithMark Lebwohl
Jun 3, 2004·Rheumatic Diseases Clinics of North America·John J Cush
Apr 3, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Brian A Baldo
Apr 3, 2013·The Journal of Rheumatology·Orla M Ni MhuircheartaighCynthia S Crowson
Dec 4, 2009·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Shawn VasooKamaljit Singh
Dec 17, 2005·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Arul GaneshanDavid Smith
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Wei Shen LimI D Johnston
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Hiroshige MikamoTeruhiko Tamaya
© 2022 Meta ULC. All rights reserved